Vopratelimab
- CAS No.
- 2039148-04-2
- Chemical Name:
- Vopratelimab
- Synonyms
- JTX 2011;Vopratelimab;Vopratelimab (anti-ICOS);Research Grade Vopratelimab;Research Grade Vopratelimab (DHJ92101)
- CBNumber:
- CB38081077
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | QXN20J93AH |
| NCI Drug Dictionary | vopratelimab |
Vopratelimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0623964 | Vopratelimab 99.98% | 2039148-04-2 | 1mg | $542 | 2026-06-04 | Buy |
| ChemScene | CS-0623964 | Vopratelimab 99.98% | 2039148-04-2 | 5mg | $1408 | 2026-06-04 | Buy |
| ChemScene | CS-0623964 | Vopratelimab 99.98% | 2039148-04-2 | 10mg | $2167 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1944780 | Vopratelimab Antibody 98.34%(SEC-HPLC) | 2039148-04-2 | 1mg | $460 | 2026-05-06 | Buy |
| Biorbyt Ltd | orb1944780 | Vopratelimab Antibody 98.34%(SEC-HPLC) | 2039148-04-2 | 5mg | $1110 | 2026-05-06 | Buy |
Vopratelimab Chemical Properties, Uses, Production
Uses
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].
in vivo
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model[1].
| Animal Model: | Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1] |
| Dosage: | 0.25-0.3 mg/kg |
| Administration: | Intraperitoneal injection; twice a week, for 2 weeks |
| Result: | Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model. |
References
[1] Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595. DOI:10.1371/journal.pone.0239595
Vopratelimab Preparation Products And Raw materials
Raw materials
Preparation Products
Vopratelimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Latest Price from Vopratelimab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-23 | Vopratelimab
2039148-04-2
|
$330.00-1320.00 | 98.34% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Vopratelimab
2039148-04-2
- $330.00-1320.00
- 98.34% (SEC-HPLC)
- TargetMol Chemicals Inc.
